Yesid Alvarado Valero MD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Physician

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-794-4364

Dr. Alvarado Valero is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Alvarado Valero's full profile Already have an account?

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2011
Texas Tech University Health Sciences Center at LubbockResidency, Internal Medicine, 2003 - 2006
Juan N. Corpas School of MedicineClass of 1994

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2026 - Present
GA State Medical License 2026 - 2028
AZ State Medical License 2026 - 2027
LA State Medical License 2026 - 2027
MS State Medical License 2026 - 2027
OK State Medical License 2020 - 2027
TN State Medical License 2026 - 2027
TX State Medical License 2007 - 2027
AL State Medical License 2026 - 2026
NM State Medical License 2006 - 2007
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2014-2015

Clinical Trials

A Study of TAS1440 With ATRA in Subjects With r/r AML Start of enrollment: 2020 Mar 15
TERMINATED
PHASE1
Roles: Contact
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Start of enrollment: 2018 Nov 07
COMPLETED
PHASE2
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

6 citations
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.
Jennifer Croden, Wei-Ying Jen, Jennifer Marvin-Peek, Lianchun Xiao, Ian M Bouligny
Leukemia. 2025-10-01
4 citations
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.
Yesid Alvarado-Valero, Rachel J Cook, Shira N Dinner, Michael Keng, Kebede H Begna
Blood Neoplasia. 2025-08-01
16 citations
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial.
Sonja Loges, Michael Heuser, Jörg Chromik, Grerk Sutamtewagul, Silke Kapp-Schwoerer
Nature Communications. 2025-03-23

Abstracts/Posters

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Yesid Alvarado, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018